- Home
- GH vs PRIM Comparison
GH vs PRIM Comparison
Compare GH & PRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- PRIM
- Stock Information
- Founded
- GH 2011
- PRIM 1960
- Country
- GH United States
- PRIM United States
- Employees
- GH N/A
- PRIM N/A
- Industry
- GH Medical Specialities
- PRIM Water Sewer Pipeline Comm & Power Line Construction
- Sector
- GH Health Care
- PRIM Industrials
- Exchange
- GH Nasdaq
- PRIM Nasdaq
- Market Cap
- GH 4.9B
- PRIM 4.0B
- IPO Year
- GH 2018
- PRIM N/A
- Fundamental
- Price
- GH $49.14
- PRIM $74.00
- Analyst Decision
- GH Strong Buy
- PRIM Strong Buy
- Analyst Count
- GH 20
- PRIM 8
- Target Price
- GH $54.35
- PRIM $85.75
- AVG Volume (30 Days)
- GH 2.2M
- PRIM 702.5K
- Earning Date
- GH 08-06-2025
- PRIM 08-04-2025
- Dividend Yield
- GH N/A
- PRIM 0.43%
- EPS Growth
- GH N/A
- PRIM 41.89
- EPS
- GH N/A
- PRIM 3.77
- Revenue
- GH $773,996,000.00
- PRIM $6,602,243,000.00
- Revenue This Year
- GH $23.14
- PRIM $8.52
- Revenue Next Year
- GH $21.42
- PRIM $5.12
- P/E Ratio
- GH N/A
- PRIM $19.63
- Revenue Growth
- GH 28.20
- PRIM 12.45
- 52 Week Low
- GH $20.14
- PRIM $45.92
- 52 Week High
- GH $52.92
- PRIM $90.86
- Technical
- Relative Strength Index (RSI)
- GH 62.17
- PRIM 55.40
- Support Level
- GH $48.00
- PRIM $72.95
- Resistance Level
- GH $51.71
- PRIM $76.19
- Average True Range (ATR)
- GH 2.67
- PRIM 2.13
- MACD
- GH 0.39
- PRIM -0.25
- Stochastic Oscillator
- GH 78.60
- PRIM 53.99
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About PRIM Primoris Services Corporation
Primoris Services Corp is a provider of infrastructure services operating mainly in the United States and Canada. It provides a wide range of construction services, maintenance, replacement, fabrication and engineering services to a diversified base of customers. The reportable segments are the Utilities segment and the Energy segment. The Utilities segment operates in a range of services, including the installation and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communication systems. The Energy segment operates in a range of services that include engineering, procurement, and construction, retrofits, highway and bridge construction, demolition, site work, outages, pipeline construction and maintenance, and others.